Evidence map›Paper›PMID 30989413›Full record

ArticlePharmaceutical research2019

Polymeric Micellar Formulation Enhances Antimicrobial and Anticancer Properties of Salinomycin.

Carolina Sousa, Luís F Gouveia, Bruna Kreutzer, Beatriz Silva-Lima, Retsepile E Maphasa, Admire Dube, Mafalda Videira

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Carolina SousaPharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal.ORCID http://orcid.org/0000-0003-4544-5540
Luís F GouveiaPharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal.
Bruna KreutzerPharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal.
Beatriz Silva-LimaPharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal.
Retsepile E MaphasaDiscipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville, South Africa.
Admire DubeDiscipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville, South Africa.
Mafalda VideiraPharmacological and Regulatory Sciences Group (PharmaRegSci), Research Institute for Medicines (iMed.ULisboa), Faculdadde de Farmácia da Universidade de Lisboa, Lisbon, Portugal. mafaldavideira@campus.ul.pt.
University of Lisbon · PTUniversity of the Western Cape · ZA

Funding

Fundação para a Ciência e a Tecnologia ENMed/0009/2015Fundação para a Ciência e a Tecnologia (PT) ENMed/0065/2016iMed.ULisboa UID/DTP/04138/2013SimInhale COST Action MP1404
6 · The paper itself

Abstract

purposeSalinomycin (SAL) is a polyether compound that exhibits strong antimicrobial as well as anticancer activity. Nanomedicine has been at the forefront of drug delivery research with the aim of increasing the efficacy, specificity and reduce toxicity of drugs. There is an intersection between infection and cancer, and cancer patients are prone to bacterial infections. In this study, polymeric micelles were prepared using Pluronic® F127 (PM) to encapsulate SAL (PM_SAL) with the view of enhancing antimicrobial and anticancer activity.

methodsA Quality by Design (QbD) approach was utilized to synthesize PM_SAL, and nanoformulation activity was determined against bacterial (S. aureus, MRSA and E. coli). Effects on cancer cell line A549, i.e. cell viability, prevention of P-gp efflux, vimentin expression, effects on migratory ability of A549 cells. Anticancer activity was determined by ability to eradicate cancer stem-like cells.

resultsPM_SAL demonstrated only efficacy against MRSA, being even higher than that obtained with SAL. In A549 cells, a 15-fold increase in P-gp's expression as well as a significant decrease of the cell's migration, was observed.

conclusionsPM_SAL can interfere with the oncogenic protein VIM, involved in the crucial mechanisms EMT, downregulating its expression. Altogether data obtained indicates that this antibiotic and the developed polymeric micelle system is a very promising inhibitor of tumor cell growth.

Indexed as

A549 CellsAnti-Infective AgentsAntineoplastic AgentsCell ProliferationCell SurvivalDrug CarriersDrug LiberationEscherichia coliHumansMicellesNeoplastic Stem CellsParticle SizePoloxamerPolyether PolyketidesPyransStaphylococcus aureusAnti-Infective AgentsAntineoplastic AgentsDrug CarriersMicellesPoloxamerPolyether PolyketidesPyranssalinomycinVimentinAntibioticscancer stem cellsnanomedicinespolymeric micellesquality by designsalinomycin

Identifiers

PMID30989413
OpenAlexW2939232034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.